Better answers today. Better care tomorrow.
We are in the midst of a healthcare transformation away from the one-size-fits-all approach towards a more targeted, personalised approach that utilises patients’ molecular information to inform treatment decisions. NGS has emerged as the platform of choice by enabling the simultaneous assessment of all relevant biomarkers, saving time while preserving precious tissue.
Here at Thermo Fisher Scientific, we are committed to empowering any lab to bring next-generation sequencing (NGS) in-house to help realise the full promise of precision medicine.
Visit us at ESMO 2019
Connect with us at booth #410:
- Ask anything about NGS testing you have always wanted to know
- Discover why more and more labs are opting to bring NGS testing in-house and how you can do it too
- Get the latest about new and emerging biomarkers like NTRK and RET and recommended molecular profiling approaches
- Discover the central role of the molecular tumour board in determining an optimal treatment plan
Join our satellite symposium:
|Precision in practice: a new era for oncology treatment|
|Date||29 September 2019|
|Location||Santander Auditorium, Hall 3, Fira Gran Via, Barcelona, Spain|
|Session 1||Precision oncology: where are we today?
During this session, we will review the current precision oncology landscape with a focus on NSCLC and thyroid cancer, as well as the latest clinical research data on emerging biomarkers such as RET and NTRK.
|Session 2||Leading from the lab: pathology in focus
With an increasingly complex biomarker landscape, pathologists play a pivotal role in oncology. Gain expert insights on testing methodologies with a focus on NSCLC and key considerations for developing optimal testing strategies in practice.
|Session 3||The molecular tumour board: a team effort
The use of Multi Disciplinary Teams (MDTs) and effective team collaboration can lead to improved treatment outcomes. During this interactive discussion, a multidisciplinary panel will review a case study and demonstrate live how MDTs interact during a molecular tumor board and how shared perspectives can help drive better treatment decisions in practice.
|Session 4||Immuno-oncology biomarkers in the future
During this session, we will explore the latest clinical research data, and discuss possible future personalisation in immuno-oncology.
Not attending ESMO? Visit our web site www.oncomine.com to learn more or to get in touch with your local representative.
1 For in vitro diagnostic use by trained personnel in a professional laboratory.